fatty liver and magnesium

The effect of magnesium supplementation on liver enzymes , lipid profile and fasting blood glucose in patients of non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201203128753N1

Enrollment

Registered

2012-03-12

Start date

2011-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease. NAFLD

Interventions

Intervention 1: intervention groups:1 capsol of 580 miligrames magnesium oxide in a day for 3 months. Intervention 2: control groups:1capsol of lactose in aday for 3 months.

Placebo

intervention groups:1 capsol of 580 miligrames magnesium oxide in a day for 3 months

control groups:1capsol of lactose in aday for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: inclusion criteria:adults (men &women)18-59 years with fatty live and Alanine amino Transferase equal or higher than 40. exclusion criteria:kidny diseases, chronic lung disease, other hepatic disease, alcoholism.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;AST. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;ALP. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;TG. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;Chol. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;LDL. Timepoint: befor and 3 month after intervention. Method of measurement: undirected method with Friedewald.;HDL. Timepoint: befor and 3 month after intervention. Method of measurement: Enzymatic.;FBS. Timepoint: befor and 3 month after intervention. Method of measurement: Photometric.	—

Measure

Time frame

ALT. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;AST. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;ALP. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;TG. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;Chol. Timepoint: befor and 3 month after intervention. Method of measurement: photometric.;LDL. Timepoint: befor and 3 month after intervention. Method of measurement: undirected method with Friedewald.;HDL. Timepoint: befor and 3 month after intervention. Method of measurement: Enzymatic.;FBS. Timepoint: befor and 3 month after intervention. Method of measurement: Photometric.

—

Secondary

Measure	Time frame
Weight. Timepoint: befor and after 3 month of intervention. Method of measurement: scale.;Waist circumference. Timepoint: befor and 3 month of intervention. Method of measurement: meter.;Hip circumference. Timepoint: befor and 3 month after intervention. Method of measurement: meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahtab Tamimi

Ahvaz Jondi-shapur University of Medical Sciences

research@ajums.ac.ir+98 61 1338 3838

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026